miR-20a-5p在胰腺癌中的表达及作用机制研究

目的检测并分析胰腺癌组织和胰腺癌细胞株中miR-20a-5p的表达情况及对胰腺癌细胞发生、发展的影响。方法收集16对手术切除胰腺癌患者的癌组织及对应癌旁组织、5种胰腺癌细胞株及1株正常胰腺导管上皮细胞,通过实时荧光定量聚合酶链反应(quantitative realtime polymerase chain reaction,qRT-PCR)检测临床标本及胰腺癌细胞株中miR-20a-5p的表达水平;通过转染miR-20a-5p mimics及miR-20a-5p inhibitor分别上调及下调胰腺癌细胞(AsPC-1、BxPC-3)中miR-20a-5p的表达水平,采用CCK-8、EdU及流式凋亡实验检测过表达及敲低miR-20a-5p后对胰腺癌细胞活力、增殖及凋亡能力的影响。结果胰腺癌组织中miR-20a-5p的表达量显著高于癌旁组织(P0.01),5种胰腺癌细胞系中miR-20a-5p的表达量较正常胰腺细胞也明显升高(P0.05)。CCK-8及EdU实验结果显示,过表达miR-20a-5p促进胰腺癌细胞增殖能力,反之,干扰miR-20a-5p抑制胰腺癌细胞增殖。凋亡检测结果显示,过表达miR-20a-5p抑制胰腺癌细胞凋亡能力,反之,干扰miR-20a-5p促进胰腺癌细胞凋亡。结论胰腺癌组织和胰腺癌细胞系均高表达miR-20a-5p,上调miR-20a-5p能促进胰腺癌细胞增殖及抗凋亡能力。     

miR-483-3p对结直肠癌DLC1基因表达的影响

背景:抑癌基因表达抑制在肿瘤发生、发展过程中起重要作用。一些microRNAs可通过调节抑癌基因的表达影响肿瘤发生。目的:探讨miR-483-3p对结直肠癌肝癌缺失基因1(DLC1)表达的靶向调节作用。方法:纳入2012年10月~2013年4月南京鼓楼医院收治的结直肠癌患者16例,采用蛋白质印迹法检测癌组织及其相应癌旁非癌组织的DLC1表达,qRT-PCR检测miR-483-3p表达。构建含DLC1 3’非翻译区(3’UTR)的双荧光素酶报告基因质粒,在人结肠癌细胞株HCT116中验证miR-483-3p对DLC1表达的调节作用。以miR-483-3p mimic转染HEK293T细胞,采用蛋白质印迹法检测DLC1表达;以miR-483-3p mimic转染HCT116细胞,采用CCK-8实验检测细胞增殖。结果:结直肠癌组织的DLC1表达水平显著低于癌旁非癌组织,miR-483-3p表达水平显著高于癌旁非癌组织(P0.05)。miR-483-3p mimic可靶向结合DLC1的3’UTR而抑制其表达。转染miR-483-3p mimic的HCT116细胞增殖能力显著增强(P0.05)。结论:DLC1是miR-483-3p的靶基因,miR-483-3p可在转录后水平抑制DLC1表达,参与促进结直肠癌发生。     

miR-145-3p在肝癌中的表达及其对肝癌细胞生长的调控作用

背景miR-145-3p在头颈癌、肺癌和胃癌等肿瘤可发挥抑癌的作用,而其在肝癌中的表达和作用并不清楚.目的探讨miR-145-3p在肝癌中的表达及其对肝癌细胞的增殖与凋亡的调控作用.方法用RT-q PCR法检测肝癌组织、癌旁组织、肝细胞株(Hep3B、Huh-7、Hep G2和SMMC-7721)与正常肝细胞株L-02中miR-145-3p的表达水平;将miR-145-3pmimic或miR-145-3pinhibitor转入Hep3B细胞,用CCK-8法、流式细胞术、TUNEL法和Westernblot法分别检测细胞活力、细胞周期、细胞凋亡和4型黏蛋白(mucin4, MUC4)表达.用荧光素酶报告基因实验鉴定miR-145-3p的靶基因.将pc DNA-MUC4转入已转染miR-145-3p mimic的细胞,用CCK-8法和TUNEL法分别检测细胞活力与细胞凋亡.结果miR-145-3p在肝癌组织和细胞中呈低表达.过表达miR-145-3p能抑制细胞增值和G0/G1期到S期转换,促进凋亡和降低MUC4表达;而敲减miR-145-3p则作用相反. MUC4是miR-145-3p的靶基因.过表达MUC4能逆转miR-145-3p mimic对细胞存活的抑制作用.结论miR-145-3p在肝癌低表达,且其表达与T分期呈负相关.过表达miR-145-3p可抑制肝癌细胞存活与生长,而敲减miR-145-3p能促进肝癌细胞存活与生长.     

miR-151a-3p对胰腺癌细胞增殖、迁移、侵袭及凋亡的影响

目的探讨miR-151a-3p在胰腺癌细胞中的表达及miR-151a-3p表达对胰腺癌细胞增殖、迁移、侵袭及凋亡的影响。方法采用实时荧光定量聚合酶链反应(qRT-PCR)检测miR-151a-3p在三种胰腺癌细胞系的表达情况;利用脂质体转染技术将miR-151a-3p mimic和mimic NC转染至胰腺癌BxPC-3细胞中,qRT-PCR检测转染后miR-151a-3p在BxPC-3细胞中的表达水平;CCK-8法检测转染后BxPC-3细胞的增殖能力;Transwell实验检测转染后BxPC-3细胞的迁移及侵袭能力;流式细胞术检测转染BxPC-3细胞的凋亡能力。结果 qRT-PCR结果显示,3种胰腺癌细胞系中miR-151a-3p表达水平均显著升高(P0.01),其中,BxPC-3细胞中miR-151a-3p表达水平最高;转染miR-151a-3p mimic的BxPC-3细胞中miR-151a-3p表达水平显著高于mimic NC和空白组(P0.001);CCK-8实验结果显示,转染miR-151a-3p mimic的BxPC-3细胞增殖能力显著高于mimic NC和空白对照组(P0.01);Transwell实验结果显示,转染miR-151a-3p mimic的BxPC-3细胞迁移及侵袭能力显著高于mimic NC和空白对照组(P0.01);流式细胞术结果显示,转染miR-151a-3p mimic的BxPC-3细胞凋亡率显著低于mimic NC和空白对照组(P0.001)。结论 miR-151a-3p在胰腺癌细胞中高表达,过表达miR-151a-3p促进胰腺癌细胞增殖、迁移及侵袭,抑制细胞凋亡。     

MicroRNA-144-3p在胰腺癌中的表达及其对胰腺癌侵袭转移的影响

目的检测胰腺癌患者组织及胰腺癌细胞系中microRNA-144-3p(miR-144-3p)的表达及其对胰腺癌侵袭转移的影响。方法收集13对手术切除的胰腺癌及对应癌旁组织标本,实时荧光定量聚合酶链反应(quantitative real-time polymerase chain reaction,qRT-PCR)验证临床标本与4种人胰腺癌细胞系中miR-144-3p的表达;应用划痕和Transwell实验检测转染miR-144-3p模拟物(mimic)及阴性对照(mimic NC)后胰腺癌细胞PANC-1的迁移及侵袭能力;数据库预测miR-144-3p的靶基因,并用Western blotting检测miR-144-3p对E26转录因子-1(E26 transformation specific-1,ETS1)蛋白表达的影响。结果胰腺癌组织miR-144-3p的表达显著低于癌旁组织(P0.05),胰腺癌细胞系miR-144-3p的表达较正常胰腺细胞明显降低(P0.05)。划痕实验显示,mimic组划痕愈合速度明显慢于mimic NC组。Transwell迁移及侵袭实验显示,mimic组细胞迁移和侵袭能力较mimic NC组明显减弱(P0.05)。过表达miR-144-3p抑制ETS1的蛋白水平。结论 miR-144-3p在胰腺癌组织和胰腺癌细胞系中均呈低表达,上调miR-144-3p可能通过靶向抑制ETS1减弱胰腺癌细胞的侵袭转移能力。     

miR-556-3p通过调控PTEN/AKT信号通路影响肝细胞癌的转移活性

目的 通过探索miR-556-3p在肝癌细胞发生发展过程中的作用机制,以期为肝细胞癌的预防和治疗提供一个新思路。方法 取肝细胞癌组织和癌旁肝组织,采用PCR法检测miR-556-3p水平,采用免疫组化法检测磷酸酯酶与张力蛋白同源物(PTEN)表达,采用荧光素酶法检测细胞作用靶点,应用miR-556-3p mimic、miR-556-3p NC、PTEN cDNA和PTEN siRNA转染HepG2细胞,采用Western blotting法检测PTEN/AKT信号通路相关蛋白表达。采用CCK-8法检测细胞增殖能力,采用Transwell法检测细胞侵袭力,使用流式细胞术检测细胞凋亡。应用生物信息学法预测miR-556-3p对HepG2细胞PTEN/AKT通路的调控作用。结果 肝癌组织miR-556-3p水平显著低于癌旁组织(P<0.05),HepG2细胞miR-556-3p水平显著低于正常肝细胞(P<0.05);荧光素酶分析显示,PTEN是miR-556-3p的直接靶点;miR-556-3p处理的HepG2细胞增殖、侵袭和凋亡率显著低于miR NC处理组(P<0.05)...     

藤梨根提取物通过调控miR-192-5p/ARPP19轴影响结直肠癌细胞的增殖和凋亡

背景藤梨根提取物(rattan root extract,RRE)可抑制胃癌、肺癌等肿瘤细胞增殖,具有一定抗肿瘤作用,但其是否影响结直肠癌细胞的恶性表型还未知.miR-192-5p在结直肠癌组织中表达降低,且其低表达与肿瘤大小等临床病理特征相关,可作为结直肠癌诊治的潜在生物学标志物.StarBase生物信息学软件预测显示,环腺苷酸调节的磷酸化蛋白19(cAMP-regulated phosphoprotein 19,ARPP19)可能是miR-192-5p的靶基因.本研究假设RRE可通过调控miR-192-5p/ARPP19轴影响结直肠癌细胞增殖和凋亡.目的探讨RRE对结直肠癌SW480细胞增殖和凋亡的影响及作用机制.方法RRE干预SW480细胞后,MTT检测细胞增殖,流式细胞术检测细胞凋亡,蛋白质印迹法检测细胞中CyclinD1、C-caspase-3和ARPP19蛋白水平,RT-qPCR检测细胞中miR-192-5p和ARPP19 mRNA水平.转染miR-192-5p模拟物或ARPP19小干扰RNA至SW480细胞,上述相同方法观察过表达miR-192-5p或抑制ARPP19表达对SW480细胞增殖、凋亡及CyclinD1和C-caspase-3蛋白表达的影响.双荧光素酶报告基因实验验证miR-192-5p和ARPP19调控关系.结果RRE可降低SW480细胞存活率及ARPP19 mRNA和蛋白的表达(P<0.05),增加SW480细胞凋亡率及C-caspase-3蛋白和miR-192-5p的表达(P<0.05).过表达miR-192-5p或抑制ARPP19表达均可降低SW480细胞存活率及CyclinD1蛋白表达(P<0.05),而提高SW480细胞凋亡率及C-caspase-3蛋白表达(P<0.05).miR-192-5p在SW480细胞中靶向负调控ARPP19表达.抑制miR-192-5p表达可逆转RRE对SW480细胞增殖、凋亡及CyclinD1和C-caspase-3蛋白表达的影响.抑制ARPP19表达可逆转抑制miR-192-5p表达对RRE处理的SW480细胞增殖、凋亡及CyclinD1和C-caspase-3蛋白表达的影响.结论RRE可有效抑制结直肠癌SW480细胞增殖,促进细胞凋亡,其作用机制与调miR-192-5p/ARPP19轴有关.     

间充质干细胞来源的胞外囊泡通过装载miR-375对结直肠癌发生的影响机制

目的 探究间充质干细胞来源的胞外囊泡通过装载miR-375对结直肠癌发生的影响机制。方法 分离培养并鉴定结直肠癌组织中间充质干细胞,从间充质干细胞中分离并鉴定胞外囊泡。将胞外囊泡装载miR-375过表达模拟物,qRT-聚合酶链反应(PCR)检测细胞中miR-375的表达情况。培养结直肠癌细胞系SW480,将胞外囊泡和SW480细胞共培养。双荧光素酶报告分析miR-375和同源框蛋白(HOX)A3的靶向关系。qRT-PCR检测共培养后,细胞中miR-375和HOXA3 mRNA的表达情况。Western印迹检测HOXA3蛋白的表达情况。对细胞分别进行miR-375和HOXA3过表达处理,CCK-8法、Transwell实验分别检测各组细胞增殖和侵袭能力变化情况。流式细胞术检测细胞凋亡情况。结果 成功分离间充质干细胞来源的胞外囊泡,并将miR-375过表达模拟物装载至胞外囊泡。miR-375可靶向负调控HOXA3的表达。过表达miR-375后抑制SW480细胞增殖、侵袭,促进细胞凋亡,而过表达HOXA3则会促进SW480细胞增殖、侵袭,抑制细胞凋亡,且过表达HOXA3后,会阻断miR-37...     

miR-128-3p靶向xCT基因在结直肠癌中的分子机制及其与肠癌患者临床病理特征的相关性

背景结直肠癌(colorectal carcinoma, CRC)是临床上最为常见的消化系统恶性肿瘤,但结直肠癌细胞增殖和迁移的分子机制并为完全阐明.胱氨酸/谷氨酸反转运体X(cystine/glutamate antiporter, x CT)被证实在多种肿瘤中高表达并与细胞的铁死亡有关.目的探讨mi R-128-3p靶向x CT基因抑制结直肠癌细胞增殖、侵袭的分子机制及其与患者临床病理特征关系.方法癌症基因图谱(the cancer genome atlas, TCGA)、Oncomine数据库中比较胱氨酸/x CT基因在人结直肠癌及多种实体肿瘤中的表达.肿瘤免疫(tumor immune estimationresource, TIMER)数据库中分析x CT表达水平与淋巴细胞浸润程度关系.基因表达综合(gene expression omnibus, GEO)数据库下载结直肠癌患者癌组织vs癌旁组织差异表达mi RNA数据集GSE18392,筛序癌组织与癌旁组织差异表达mi RNA,筛选条件为Log2FC1, adj P0.05. micro RNA靶基因在线预测算法(Targetscan, mi RDB和Star Base)预测x CT上游靶mi RNA.GSE18392差异表达mi RNA和预测靶基因取交集得到mi R-128-3p.并采用双荧光素酶报告实验验证mi R-128-3p与x CT靶向调控关系.实时荧光定量聚合酶链反应(real time fluorescent quantitative polymerase chainreaction,RT-PCR)检测人正常肠上皮细胞及人结直肠癌细胞系、38例结直肠癌患者癌组织和癌旁组织中x CT及mi R-128-3p表达水平.溴化噻唑蓝四氮唑[3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT)]实验和划痕实验观察转染外源性mi R-128-3p-mimic后人结癌细胞(SW480)增殖和迁移能力有无改变.结果结直肠癌组织x CT表达水平显著高于癌旁正常组织(P 0.05).筛选并预测mi R-128-3p为x CT上游靶向调控基因.荧光素酶报告基因显示, mi R-128-3p可靶向结合x CT基因3’UTR区域. x CT在人结直肠癌细胞系(HT-29,SW480,Lo Vo及SW620)中的表达水平显著高于正常肠上皮细胞(NCM460),(P0.05),而mi R-128-3p在人结直肠癌细胞系中的表达水平显著低于正常肠上皮细胞异(P0.05).转染外源性mi R-128-3p mimic可显著下调SW480细胞中x CT表达水平,并抑制SW480细胞增殖和迁移能力. x CT在38例结直肠癌患者癌组织中的表达水平显著高于癌旁组织(P0.05),而mi R-128-3p在癌组织中相对表达水平显著低于癌旁组织(P0.05).癌组织中mi R-128-3p与x CT表达负相关(rpearson=-0.43,P 0.05).免疫组化显示x CT阳性表达于细胞膜,呈棕黄色颗粒,在癌组织中阳性率63.2%. x CT阳性表达与肿瘤分化(P0.05)和脉管浸润(P0.05)有关. x CT表达水平与结肠癌CD8+T细胞,中性粒细胞,树突状细胞浸润有关(P0.05),与直肠癌CD8+T细胞和中性粒细胞浸润有关(P0.05),而于其他淋巴细胞浸润水平无关(P0.05).结论x C T在结直肠癌中表达上调,m i R-128-3p可通过与x C T基因3’ U T R结合抑制肠癌细胞的增殖和迁移,mi R-128-3p/x CT通路有望成为肠癌靶向治疗新的潜在靶点.     

补体C7在结直肠癌组织中的表达及其对结肠癌细胞株增殖的影响

目的检测补体C7在结直肠癌组织中的蛋白表达,探讨补体C7对人结肠癌细胞株HCT-116、LoVo增殖的影响及其可能的机制。方法利用免疫组织化学方法分别检测50例结直肠癌患者癌组织及癌旁组织中补体C7蛋白分布与表达水平;将过表达C7质粒和C7-siRNA分别转染人结肠癌细胞株HCT-116和LoVo细胞,通过CCK-8检测C7对这两种细胞增殖的影响;通过Western blotting检测HCT-116在PI3K抑制剂LY294002处理后C7的变化。结果结直肠癌组织中补体C7蛋白表达水平明显高于癌旁组织。与空载质粒组和NC-siRNA组相比,C7过表达组细胞增殖能力明显增强,C7-siRNA组细胞增殖能力明显减弱; LY294002处理结肠癌细胞后C7蛋白表达量明显降低。结论补体C7在结直肠癌组织中明显高表达,抑制结肠癌LoVo细胞中C7基因可降低癌细胞增殖,其机制与PI3K/AKT信号通路的调控有关。     

MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway

Background

Oxaliplatin is one of the most effective chemotherapeutic drugs used for the treatment of colorectal cancer (CRC). However, intervention that attenuates the resistance of oxaliplatin is still required in the treatment of CRC.

Aims

To investigate the role of miR-325 in changing the oxaliplatin sensitivity to CRC cells.

Methods

Expression of miR-325 in colorectal cancer tissues and cell lines was measured by using qRT-PCR analysis. Cytotoxicity of oxaliplatin to control or miR-325-overexpressed HT29 and SW480 cells was evaluated by CCK-8 assays. Luciferase reporter assay was used to confirm the regulation of miR-325 on HSPA12B. Flow cytometry was performed to detect the mitochondrial membrane potential and cell apoptosis.

Results

Expression of miR-325 was decreased in colorectal cancer tissues and cell lines. However, overexpression of miR-325 can decrease the 50% inhibiting concentration of oxaliplatin to colorectal cancer cell lines HT29 and SW480. Mechanically, we confirmed that miR-325 targeted HSPA12B in colorectal cancer. Therefore, overexpression of miR-325 inhibited the phosphorylation of PI3K and AKT and decreased the expression of Bcl-2 to promote the oxaliplatin-induced mitochondrial apoptosis in colorectal cancer.

Conclusions

MiR-325 sensitizes the colorectal cancer cells to oxaliplatin-induced cytotoxicity through the HSPA12B/PI3K/AKT/Bcl-2 pathway.

     

Down-regulation of miR-141 in gastric cancer and its involvement in cell growth

Purpose  Human microRNA-141 (miR-141), a member of the miR-200 family, has been reported to be associated with various human malignancies. However, it remains unknown whether miR-141 is involved in the pathogenesis of gastric cancer. Therefore, we examined the expression of miR-141 in gastric cancer tissues and the effect of miR-141 overexpression on cancer cell proliferation. Methods  The expression level of miR-141 in 35 pair-matched gastric neoplastic and adjacent non-neoplastic tissues, and in 5 gastric cancer cell lines were examined by quantitative real-time PCR. The growth of MGC-803 cells transfected with miRNA precursor was examined by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazoliumbromide) assay. Results  MiR-141 was significantly down-regulated in 80% (28/35) of primary gastric cancer tissues compared with pair-matched adjacent non-tumor tissues (P < 0.01). The expression of miR-141 was also found to be substantially reduced in several human gastric cancer cell lines such as MGC-803, HGC-27, SGC-7901 and BGC-823 cells. Overexpression of miR-141 with its precursors significantly inhibited the proliferation of gastric cancer cells. Conclusions  These results suggest that miR-141 may be involved in the development of gastric cancer through its inhibitory effect on cell proliferation. Electronic supplementary material  The online version of this article (doi:) contains supplementary material, which is available to authorized users.     

Functional role of long non-coding RNA CASC19/miR-140-5p/CEMIP axis in colorectal cancer progression in vitro

BACKGROUND Long non-coding RNAs(lncRNAs) are widely involved in tumor regulation.Nevertheless, the role of the lncRNA cancer susceptibility 19(CASC19) in colorectal cancer(CRC) has yet to be fully clarified.AIM To explore the effect of CASC19 on proliferation and metastasizing ability of CRC cells.METHODS CASC19 expression in human CRC tissues, pair-matched adjacent normal colon tissues, and CRC cells was detected using quantitative real-time PCR(qRT-PCR).CASC19 expression, as well as its relation to overall survival, was extrapolated by Kaplan-Meier survival analysis together with multivariable Cox regression assay.In vitro experiments were performed to confirm whether CASC19 regulates CRC cell invasion, migration, proliferation, and apoptosis.RESULTS CASC19 expression was markedly upregulated in CRC tissues and CRC cell lines(P < 0.05). qRT-PCR revealed that CASC19 expression was higher in 25 tissue samples from patients with aggressive CRC compared with the 27 tissue samples from patients with nonaggressive CRC(P < 0.05). Higher CASC19 expression was associated with poorer patient prognoses. Furthermore, in vitro experiments demonstrated that CASC19 overexpression enhanced CRC cell invasion,migration, and proliferation. CASC19 overexpression enhanced the expression of cell migration inducing hyaluronidase 1(CEMIP) and epithelial-mesenchymal transition markers. MiR-140-5 p was found to be able to bind directly to CASC19 and CEMIP. Overexpression of miR-140-5 p reversed the effect of CASC19 on cellproliferation and tumor migration, as well as suppressed CASC19-induced CEMIP expression.CONCLUSION CASC19 positively regulates CEMIP expression through targeting miR-140-5 p.CASC19 may possess an oncogenic function in CRC progression, highlighting its potential as an essential biomarker in CRC diagnosis and therapy.     

Circ_0000291 contributes to hepatocellular carcinoma tumorigenesis by binding to miR-1322 to up-regulate UBE2T

Background and objectivesCircular RNAs (circRNAs) are identified to show important regulatory functions in cancer biology. We attempted to analyze the role of circ_0000291 in hepatocellular carcinoma (HCC) progression and its related mechanism.MethodsThe circular characteristic of circ_0000291 was tested using exonuclease RNase R. Cell proliferation was analyzed by 5-Ethynyl-2’-deoxyuridine (EdU) incorporation and colony formation assays. Cell apoptosis was measured by flow cytometry and a caspase 3 activity assay kit. Transwell assays were performed to analyze cell migration and invasion abilities. Sphere formation assay was conducted to analyze cell stemness. Dual-luciferase reporter and RNA-pull down assays were conducted to verify the interaction between microRNA-1322 (miR-1322) and circ_0000291 or ubiquitin conjugating enzyme E2 T (UBE2T).ResultsCirc_0000291 was markedly up-regulated in HCC tissues and cell lines. HCC patients with high expression of circ_0000291 displayed a low survival rate. Circ_0000291 knockdown restrained the proliferation, migration, invasion, and stemness and induced the apoptosis of HCC cells. Circ_0000291 directly interacted with miR-1322 and negatively regulated miR-1322 expression. Circ_0000291 knockdown-mediated anti-tumor impacts in HCC cells were largely overturned by the interference of miR-1322. miR-1322 directly paired with the 3’ untranslated region (3’UTR) of UBE2T, and UBE2T was negatively regulated by miR-1322. UBE2T overexpression largely reversed circ_0000291 silencing-induced effects in HCC cells. Circ_0000291 positively regulated UBE2T expression by absorbing miR-1322 in HCC cells. Circ_0000291 silencing notably reduced the tumorigenic potential in vivo.ConclusionCirc_0000291 facilitated HCC progression by targeting miR-1322/UBE2T axis, which provided novel potential biomarkers and targets for HCC patients.     

Circ-PRMT5 enhances the proliferation,migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis

Introduction and objectivesCircular RNA (circRNA) has been demonstrated as a critical regulator in human cancer, including hepatocellular carcinoma (HCC). Nevertheless, the role of circ-PRMT5 in HCC remains largely unknown.Patients or materials and methodsThe real-time quantitative polymerase chain reaction (RT-qPCR) was performed to assess the expression levels of circ-PRMT5, miR-188-5p and anti-Hexokinase II (HK2) in HCC tissues and cells. The cell proliferation, migration and glycolysis were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazol-3-ium bromide (MTT), transwell migration assay, and indicated kits, respectively. The interaction relationship between miR-188-5p and circ-PRMT5 or HK2 was analyzed by the bioinformatics database, dual-luciferase reporter assay, and RNA immunoprecipitation (RIP) assay. The western blot assay was used to analyze the expression level of HK2. The functional role of circ-PRMT5 in vivo was assessed by a xenograft experiment.ResultsCirc-PRMT5 was elevated in HCC tissues and cells than matched control groups. Furthermore, loss-of-functional experiments revealed that the silencing of circ-PRMT5 could repress proliferation, migration, glycolysis in vitro and tumor growth in vivo. Moreover, we also confirmed that overexpression of circ-PRMT5 abolished the effects on HCC cells induced by upregulating miR-188-5p. In addition, overexpression of miR-188-5p could repress the development of HCC. More importantly, HK2 was a target gene of miR-188-5p, and miR-188-5p regulated proliferation, migration, glycolysis of HCC cells by specifically binding to HK2. Mechanistically, circ-PRMT5 could act as a sponge of miR-188-5p to regulate the expression of HK2.ConclusionIn summary, circ-PRMT5 might play a key role in proliferation, migration, glycolysis of HCC cells via miR-188-5p/HK2 axis, which indicated that circ-PRMT5 might be a potential therapeutic target for HCC treatment.     

MiR-628–5p Inhibits Cervical Carcinoma Proliferation and Promotes Apoptosis by Targeting VEGF

BackgroundIt has been reported that the dysregulation of microRNAs (miRNAs) is implicated in the biological processes of diverse diseases, including the tumorigenesis of human cancers. MicroRNA-628–5p (miR-628–5p) is differentially expressed and plays a critical role in several cancers, but the role of miR-628–5p in cervical cancer has not been well studied.MethodsThe TCGA database and RT-qPCR were used to evaluate the expression profile of miR-628–5p in cervical cancer tissues. Transfection efficiency of synthetic miRNAs was detected using RT-qPCR. The biological effects of miR-628–5p on cervical cancer cells were assessed by the CCK-8 assay, flow cytometry, western blot analysis, and the tube formation assay. The expression levels of key proteins involved in cell apoptosis, the cell cycle and the PI3K pathway were analyzed by western blot analysis. Bioinformatic analysis and the luciferase reporter assay were performed to investigate the targeted relationship between miR-628–5p and vascular endothelial growth factor (VEGF).ResultsMiR-628–5p was downregulated and negatively correlated with Ki-67 expression in cervical cancer tissues, and its low level predicted poor survival of patients. Functional assays indicated that miR-628–5p inhibited cell proliferation and promoted cell apoptosis. Mechanically, VEGF was verified to be a downstream target of miR-628–5p. Moreover, overexpression of VEGF could reverse the effects of miR-628–5p on VEGF/PI3K/AKT signaling, cell proliferation, apoptosis, the cell cycle and angiogenesis in cervical cancer.ConclusionsMiR-628–5p inhibited cervical cancer cell proliferation and promoted apoptosis by targeting VEGF.